MaxCyte, Inc. is a cell-engineering focused company providing solutions to advance the discovery, development and commercialization of cell therapeutics. It leverages its cell engineering technology platform to enable the programs of its biotechnology and pharmaceutical company customers who are engaged in cell therapy. Its ExPERT platform, which is based on its Flow Electroporation technology, is designed to support the expanding cell therapy market and can be utilized across the continuum of the cell therapy sector, from discovery and development through commercialization of next-generation, cell-based medicines. The ExPERT family of products includes four instruments, the ATx, STx, GTx and VLx; a portfolio of proprietary related processing assemblies or disposables; and software protocols, all supported by a worldwide intellectual property portfolio. It also provides comprehensive off-target risk assessment solutions for gene editing, through ONE-seq and GUIDE-seq platforms.
企業コードMXCT
会社名MaxCyte Inc
上場日Mar 29, 2016
最高経営責任者「CEO」Mr. Maher Masoud, J.D.
従業員数114
証券種類Ordinary Share
決算期末Mar 29
本社所在地9713 Key West Avenue,
都市ROCKVILLE
証券取引所NASDAQ Global Select Consolidated
国United States of America
郵便番号20850
電話番号13015175556
ウェブサイトhttps://www.maxcyte.com/
企業コードMXCT
上場日Mar 29, 2016
最高経営責任者「CEO」Mr. Maher Masoud, J.D.
過去5年間の配当金総支払額は
0.00
米ドルである。

データなし